3 results
The primary objective of this study is to evaluate the clinical performance of the VENTANA PD-L1 (SP263) CDx Assay in terms of its ability to identify patients with non-squamous stage IV or recurrent NSCLC who may benefit from treatment with…
To evaluate the performance of the GRAIL NSCLC ctDNA Assay when used to identify patients with stage I adenocarcinoma NSCLC who are ctDNA positive as part of the screening process for the clinical study TROPION-Lung12.
To support the AstraZeneca ARTEMIDE-Gastric01 clinical trial by testing for PD-L1 and HER2 expression in FFPE tumor specimens for eligibility and stratification.The primary objective of this clinical performance study is to evaluate the…